BioNTech Falls Short In Jittery IPO Market
Investors also readjust to firm's unproven pipeline
After ADC Therapeutics
You may also be interested in...
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
Public Company Edition: At the J.P. Morgan Healthcare Conference and Biotech Showcase it was noted that the US IPO market is likely to be less active in the second half of the year as election risk chills investment. Also, Apellis leads recent follow-on offerings.
As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.